Company logo

MNMD - Mind Medicine (MindMed) Inc.

NASDAQ -> Healthcare -> Biotechnology
New York, United States
Type: Equity

MNMD price evolution
MNMD
(in millions $) 31 Jan 2024 30 Oct 2023 30 Jul 2023 1 May 2023
Current assets
Cash $99.7 $117.7 $116.89 $129.41
Short term investments
Net receivables
Inventory
Total current assets $103.87 $120.09 $119.79 $132.41
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $124.54 $141.55 $142.09 $155.53
Current liabilities
Accounts payable $4.14 $7.69 $8.58 $2.32
Deferred revenue
Short long term debt
Total current liabilities $32.25 $31.15 $35.12 $24.1
Long term debt $0.03 $14.07
Total noncurrent liabilities
Total debt
Total liabilities $46.41 $45.57 $36.11 $25.18
Shareholders' equity
Retained earnings -$290.2 -$266.34 -$248.41 -$219.28
Other shareholder equity $0.34 $0.78 $0.36 $0.64
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 30 Jan 2021
Current assets
Cash $99.7 $142.14 $133.54 $80.09
Short term investments
Net receivables
Inventory
Total current assets $103.87 $146.06 $137.22 $81.52
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $124.54 $169.99 $164 $81.52
Current liabilities
Accounts payable $4.14 $2.11 $4.18 $2.02
Deferred revenue
Short long term debt
Total current liabilities $32.25 $17.89 $10.41 $3.01
Long term debt $0.03
Total noncurrent liabilities
Total debt
Total liabilities $46.41 $19.08 $12.34 $5.65
Shareholders' equity
Retained earnings -$290.2 -$194.47 -$137.67 -$44.64
Other shareholder equity $0.34 $0.63 $1.05 $0.28
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense
Net income
Net income
Income (for common shares)
(in millions $) 31 Jan 2022 30 Jan 2021 31 Jan 2020 1 Oct 2018
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $93.85 $5.43 $0.88
Operating income
Income from continuing operations
EBIT
Income tax expense -$1.16
Interest expense -$0.45 $0.03 $0
Net income
Net income -$93.04 -$35.34 -$5.47 -$0.88
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.3
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $58.63 $0.42 -$0.17 $98.82
Effect of exchange rate -$0.36 -$0.23 -$0.04 $0.74
Change in cash and equivalents $20.98 -$27.8 -$13.07 $53.44
(in millions $) 31 Jan 2022 30 Jan 2021 31 Jan 2020 1 Oct 2018
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.3 $0.55
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $98.82 $9.9 $0.32
Effect of exchange rate $0.74 $0.02
Change in cash and equivalents $53.44 $6.7 $0.16
Fundamentals
Market cap $390.46M
Enterprise value N/A
Shares outstanding 41.10M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share 2.43
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 3.22
Quick ratio N/A